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The cell’s own antioxidant response element (ARE) can be used to evaluate the complications of diabetes mellitus. The hypothesis that
a synthetic ARE could be used as a genetic switch, or biosensor, to turn on and oﬀ therapeutic genes is tested herein. Mitochondrial
oxidative stress (MOS) has been hypothesized as one of the earliest insults in diabetes. Fluorescent probes used to monitor MOS revealed
that the addition of glucose at physiological levels to cultures of endothelial cells was able to induce MOS above normal levels and in a
dose-dependant manner. Additional data showed that increased glucose levels activated the ARE-GFP in a dose-dependant manner.
These data support the hypothesis that the induction of MOS is more sensitive to hyperglycemia than the induction of the ARE. Delivery
of an ARE-GFP construct with nanoparticles to the eye was successful using sub-retinal injection. This ARE-GFP/nanoparticle con-
struct was functional and reported the activation of the ARE in diabetic rat retinal pigment epithelium (RPE). These data support
the use of nanoparticle-delivered biosensors for monitoring the oxidative status of tissues in vivo.
 2007 Elsevier Ltd. All rights reserved.
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In the United States, the leading cause of new blindness
in people 20–74 years of age is diabetic retinopathy. Prior
work has demonstrated that both endothelial cells and
pericytes undergo apoptosis in human diabetic retina and
in a rat model of diabetes (Mizutani, Kern, & Lorenzi,
1996). This eventually results in the acellular capillaries
that occur early diabetic in retinopathy. These collagenous
tubes no longer move blood and adjacent retina becomes
hypoxic. Hypoxic retina in turn produces vascular endo-
thelial cell growth factor (VEGF), which stimulates
increased vascular permeability and eventually retinal neo-
vascularization. Prevention of acellular capillary formation
could prevent proliferative diabetic retinopathy.0042-6989/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
doi:10.1016/j.visres.2007.09.019
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(G.A. Lutty).An alternative to hyperglycemia-induced cell death
causing acellular capillaries is that vaso-occlusions in retina
and choroid contribute to capillary loss and neural dys-
function in retina. Adhesion of leukocytes to vascular
endothelium could initiate capillary occlusion (Lutty &
Ogura, 2003). Diabetic leukocytes demonstrate increased
adhesion (Setiadi, Wautier, Courillon-Mallet, Passa, &
Caen, 1987) and are more rigid than leukocytes from
non-diabetics (Kantar, Giorgi, Curatola, & Fiorini,
1991). Therefore, once adherent they could potentially
obstruct narrow capillary lumens, especially those with
poor vasotonia due to thickened basement membrane
and loss of pericytes, which occurs in diabetic retinopathy
(Yanoﬀ, 1969). In diabetics, increased numbers of poly-
morphonuclear leukocytes (PMN’s) are in the activated
state, a state in which they express molecules modulating
their adherence to endothelial cells (Wierusz-Wysocki
et al., 1987). If activated PMN adhere to endothelial cells,
oxygen radical-mediated injury to endothelial cells occurs,
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vated diabetic PMN produce more superoxide radicals
than non-diabetic PMN (Wierusz-Wysocki et al., 1987).
In an experimental rat model of diabetes, there was
increased adherence and diapedesis of leukocytes (Schro¨-
der, Palinski, & Schmid-Scho¨nbein, 1991).
Brownlee proposed that themajormolecularmechanisms
implicated in glucose-mediated vascular injury reﬂect a sin-
gle hyperglycemia-induced process of overproduction of
superoxide by the mitochondrial electron transport chain
(Brownlee, 2001). Mitochondria play a central role in apop-
tosis triggered by chemical stimuli. Following exposure of
the cells to an apoptogenic agent, the mitochondrial outer
membrane destabilizes. Reactive oxygen species (ROS) are
involved in the destabilization of the mitochondrial mem-
brane. Hyperglycemia can be considered an apoptogenic
agent in that it induces oxidative stress that results in mito-
chondrial membrane depolarization and induction of apop-
tosis. This has been documented in peripheral nerve by
Vincent et al. (Vincent, Brownlee, & Russell, 2002) and in
endothelial cells byMizutani (Mizutani et al., 1996). Overex-
pression of uncoupling proteins prevents glucose-induced
transient mitochondrial membrane hyperpolarization, reac-
tive oxygen species, and induction of apoptosis (Vincent,
Olzmann, Brownlee, Sivitz, & Russell, 2004).
Most diseases have a component of oxidative stress, but
cancer researchers have pioneered the use of antioxidants
for therapeutics. Induction of the ARE has been a theme
of cancer prevention and ARE investigation, since the dis-
covery of strong ARE modulators, e.g. tert-butylhydroqui-
none and sulforaphane (Kraft, Johnson, & Johnson, 2004;
Talalay, Fahey, Holtzclaw, Prestera, & Zhang, 1995). Previ-
ous work has shown that the ARE can be functional while
tethered to a nanoparticle and this system can be used to
detect the cellular ARE response to pathogenic stimuli
in vitro (Prow, Grebe, et al., 2006; Prow, Kotov, Lvov, Rijn-
brand, & Leary, 2004; Prow, Smith, et al., 2006). This study
focuses on the use of nanoparticle-deliveredARE to regulate
the expression of reporter genes to speciﬁcally detectMOS in
diabetes (Fig. 1). The data show that endothelial cells in cul-
ture do experienceMOSwith increased glucose and that fur-
ther increases in glucose activate the ARE. Diabetic rats
were used to evaluate nanoparticle-delivered biosensors for
oxidative stress. These experiments showed that the nano-
particle-ARE construct was functional in vivo and revealed
that diabetes is a powerful inducer of the ARE.2. Materials and methods2.1. Cell culture
Human retinal microvascular endothelial cells (HREC, Cell Systems,
Seattle, WA) were maintained in Dulbecco’s modiﬁed Eagle’s medium/
Ham’s F12 (DMEM/F12) medium containing 10% FBS and 1% penicil-
lin–streptomycin–fungizone at 37 C in a 5% CO2 environment. Endothe-
lial cells were passaged by washing with phosphate buﬀered saline
followed by trypsin digestion (0.25% trypsin). The cells were then washedwith complete medium before plating. Endothelial cells were passaged less
than three times for these experiments. All cell culture reagents were pur-
chased from Invitrogen (Carlsbad, CA).
2.2. In vitro transfection and polyclonal selection
The cells were transfected after being cultured for at least 24 h and only
when they were 70–80% conﬂuent. Cells were transfected with Lipofect-
amine 2000 (Invitrogen). At the time of transfection, the cells were washed
three timeswithDMEM/F12. TheDNA (4 lg for a 6-well plate) was diluted
in 250 ll of Opti-MEM and mixed gently. The Lipofectamine 2000 was
mixed gently before use. Lipofectamine 2000 (5 ll for a 6-well plate) was
mixedwith 250 ll of Opti-MEM in a separate tube. TheDNAandLipofect-
amine 2000 tubes were incubated at room temperature for 5 min. After
5 min, the diluted DNA and Lipofectamine 2000 were combined andmixed
gently. This mixture was incubated at room temperature for 20 min. The
media was removed from the culture and the DNA/Lipofectamine 2000
complex was added. Growth media was replaced after 4–6 h and the cells
incubated for 24 h prior to experimentation or selection. Selection was
accomplished by supplementing growth media with 500 lg/ml G418 (Invit-
rogen) for one week and maintenance with 250 lg/ml G418 thereafter.
2.3. Flow cytometry
Flow cytometry was used to assess the expression of ARE-driven
EGFP in vitro. These adherent cells were trypsinized and then washed
prior to ﬂow cytometry. Cells were run live in all cases. Flow cytometry
was done on a BD FACScan in the JHU School of Medicine Flow Cytom-
etry and Cell Sorting Core Facility, using channel FL1 for EGFP ﬂuores-
cence. WinMDI was used to analyze the data. Experiments were run in
triplicate in 6-well plates. After trypsinizing, the three wells were combined
to increase cell number and then analyzed. A minimum of 5000 events
were captured for each ﬁle.
2.4. Nanoparticle construction
Biosensor-tethered nanoparticles were constructed as described previ-
ously (Prow, Grebe, et al., 2006; Prow, Smith, et al., 2006). Biotin-labelled
PCR products were generated from a pARE-GFP template generously
donated by William Fahl (University of Wisconsin, Madison, WI) and
Ming Zhu (Arizona Cancer Center, Tuscon, AZ). The forward oligonu-
cleotide had a single biotin at the 5 0 end and the sequences were as follows:
forward 5 0-TAG TTA TTA ATA GTA ATC-3 0, reverse 5 0-TAC ATT
GAT GAG TTT GGA-3 0 (Integrated DNA Technologies, Inc., Coralville,
IA). Ten milliliters of PCR was generated using Red Taq (Sigma, St.
Louis, MO) under the manufactures suggested concentration of reagents.
The PCR was carried out in 96-well plates. A typical PCR cycle consisted
of denaturing at 94 C for 30 s, annealing at 65 C for 30 s and extension
for 2 min at 72 C. Biotin-labelled PCR products were tethered to strepta-
vidin-coated magnetic nanoparticles (MNP, Miltenyi Biotech, Inc.,
Auburn, CA). The magnetic nanoparticles were incubated with the bio-
tin-labelled PCR fragments at about 30 ng of 1.5 kb TAP per 1 ll of nano-
particles. The mixture was allowed to incubate at room temperature for
30 min. During that time, the magnetic column (Miltenyi Biotech, Inc.)
was prepared by washing once with 100 ll of the included nucleic acid buf-
fer and three times with 100 ll Opti-MEM (Invitrogen). Once washed, the
column was loaded with the DNA nanoparticle mixture. The column was
then washed three times with 100 ll Opti-MEM. The nanoparticles were
eluted by removing the column from the magnet and adding 100 ll of
Opti-MEM. This solution was then ready for injection.
2.5. MOS assay
The concentration of the CM-H2TMRos (Invitrogen) probe was
empirically determined to be 2 lM. The probe was prepared in complete
media. For hand counting studies, the cells were cultured on coverslip
chamber slides. The media containing the ﬂuorescent probe was
Fig. 1. Overview of the ARE-GFP and MOS in diabetes. (A) In the normal state, Nrf2 (green triangle) is retained in the cytoplasm by Keap1 (red
octagon). In diabetes, the mitochondria undergoes MOS (red mitochondria) (B). Next, the MOS induces cellular reactive oxygen species (ROS) (yellow),
both of which can inactivate Keap1 and allow Nrf2 to bind the ARE in the nucleus (B). MOS and ROS activated ARE and other cell stress pathways
induce the expression of antioxidant enzymes and the EGFP reporter protein from the ARE-GFP (arrow, green, C). The antioxidant enzymes attempt to
neutralize the ROS and the MOS (C) to return the cell to normal levels of ROS (D). If not controlled, these events are thought to reoccur and cycle from
(B) to (D).
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normal culture conditions. Once the cells were loaded, they were washed
brieﬂy in complete media and incubated for an additional 10 min. The
cells were monitored with an inverted ﬂuorescence microscope equipped
with a Cy3 ﬁlter set to determine the optimal dye concentration and incu-
bation times. The cell media was changed to media without phenol red
prior to evaluation with confocal microscopy.
2.6. Animal studies
Male Lewis rats aged 8 weeks, 180–220 g, were maintained at 22 C,
30–70% humidity, and acclimatized to a 12-h light cycle. A total of 12 rats
were randomly assigned to two groups: Streptozotocin (STZ, St. Louis,
MO) and vehicle treated. The rats were fed normal chow diet that con-
tained 5% fat, 19% protein, and 5% crude ﬁber. The Streptozotocin group
was treated with an intraperitoneal injection of Streptozotocin (30 mg/kg
diluted in 0.1 mol/L sodium citrate buﬀer, pH 4.5). The vehicle treated
animals were injected with the buﬀer only. Plasma glucose testing was
done after overnight fasting with a One Touch Ultra glucometer (Lifescan,
Burnaby, BC, Canada) three days post STZ injection. Animals with a
blood glucose level of 300 g/dL were considered diabetic.
2.7. Sub-retinal injection
All procedures were performed in accordance with the ARVO state-
ment for use of animals in ophthalmologic and vision research. Prior to
injection, the animals were anesthetized with a 1:1 dilution of 20 mg/ml
xylazine and 100 mg/ml ketamine (Phoenix Scientiﬁc, Inc., St. Louis,
MO). The pupils were dilated with 1% tropicamide and 2.5% phenyleph-
rine HCl (Akorn, Inc., Somerset, NJ) and 0.5% tetracaine HCl (Phoenix
Pharmaceutical, Inc., St. Joseph, MD) was applied for topical anesthesia.
Sub-retinal injections were done with a 1-cc syringe using a blunt, plastic,
30 gauge tube. Once the retina was reached, 50 ll was injected slowly
resulting in a bleb-shaped elevation in retina. Sub-retinal injections were
given 2 disk diameters inferior to the optic nerve. Bacitracin Zinc and
Polymyxin B Sulfate ophthalmic ointment (Akorn, Inc., Somerset, NJ)
was applied to both eyes immediately after surgery. The animals were sac-riﬁced three days after sub-retinal injection by a lethal intra-venous injec-
tion of 1 ml Beuthanasia (Schering-Plough, Inc., Kenilworth, NJ). The
eyes were then removed, injected with 1 ml of 2% paraformaldehyde in
0.1 M phosphate buﬀer, and placed in 30 ml of 2% paraformaldehyde in
0.1 M phosphate buﬀer for one hour.
2.8. Confocal micrsocopy
Confocal analysis was done on a Zeiss 510 META confocal micro-
scope (Carl Zeiss MicroImaging, Inc., Thornwood, NY) in the Wilmer
Imaging Core Facility. Excitation wavelengths include 405, 488, 514,
543, and 633 nm depending on the ﬂuorescent probes used, e.g. 405 nm
excitation and 420–480 nm emission bandpass for Hoechst 33342,
488 nm excitation and 505–530 nm emission bandpass for EGFP, and
543 nm for CM-H2TMRos with 560–615 nm emission bandpass. Appro-
priate emission wavelengths were used for each ﬂuorochrome used. Cells
were analyzed with either 5, 10, 20, 40, 63, or 100· objectives. Multispec-
tral confocal microscopy was used as a validation tool for both biosensor
targeting to separate overlapping spectra and autoﬂuorescence from bona
ﬁde labelling. The method of spectral deconvolution was developed at
JPL/Cal Tech. (Pasadena, CA) and was implemented in a new generation
of multispectral confocal microscope (Model 510 META, Zeiss, Inc.). The
‘‘emission ﬁngerprinting’’ algorithm works by ﬁtting the spectral compo-
nents over low or non-overlapping portions of the combined spectrum
of a multicolor image. The components are appropriately weighted so that
the combination of color components matches the overall spectrum from
the image pixel-by-pixel in each image plane.3. Results
3.1. MOS and ARE activity in human retinal endothelial
cells exposed to hyperglycemia
Theoretically, mitochondrial oxidative stress should be
detected ﬁrst through CM-H2TMRos and then ARE-med-
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model, if the cell does not recover from hyperglycemia or
MOS/ROS, there tends to be accumulation of GFP, fol-
lowed by apoptosis, or programmed cell death (PCD). At
this stage, the mitochondria is depolarized and, therefore,
does not accumulate CM-H2TMRos resulting in low or
no mitochondrial ﬂuorescence. These events are shown
through confocal microscopy in Fig. 2. Cultured endothe-
lial cells were exposed to three diﬀerent concentrations of
glucose, 5, 10, and 30 mM. Normal glucose levels for these
cells are 5 mM and there are no visible signs of MOS nor
ARE activity. However, MOS positive cells were present
when endothelial cells were exposed to 10 and 30 mM glu-
cose for three days. The ARE was activated in cells treated
with 30 mM glucose for three days.3.2. Dose-dependant activation of the ARE and MOS in
hyperglycemia
If the ARE can be used for detection oxidative stress
in vivo, activation of the ARE during diabetes should be
glucose dose-dependant. Fig. 3 indicates that ARE activa-
tion is dose dependant with respect to glucose level andFig. 2. MOS and ARE activity in hyperglycemic HREC. These confocal imag
glucose (5, 10, and 30 mM) for three days. The cells were stained with Hoechst
red). ARE-GFP activity is also shown (lower panels, ARE, green).closely follows MOS as measured by CM-H2TMRos ﬂuo-
rescence in HREC. There is also a dose-dependant decrease
in the number of cells per ﬁeld of view (FOV). This indi-
cates that the cells are sensitive to hyperglycemia-mediated
MOS and cannot mitigate its pathogenic eﬀects. The cell
count data has been normalized to the 5-mM glucose group
(normal growth media). The large error bars in the
hyperglycemia groups (10–55 mM glucose) are indicative
of the reduced number of cells that could be counted. Addi-
tionally, these cells were derived from a single ﬂask of
ARE-GFP transfected HREC that were brieﬂy selected
with G418. Therefore, these cells are a polyclonal line
and have varying capacities to use the ARE.3.3. Relationship between MOS and ARE activation in
cultured endothelial cells
Data from endothelial cells transiently transfected with
pARE-GFP were stained with CM-H2TMRos, treated
with diﬀerent levels of glucose for 24 h and analyzed by
ﬂow cytometry (Fig. 4). Each bar represents the data gath-
ered from 3 wells of endothelial cells that were combined
just before analysis. Cells that had levels of ﬂuorescencees are of a ARE-GFP polyclonal HREC line exposed to diﬀerent doses of
33342 (top panels, nuclei, blue) and CM-H2TMRos (middle panels, MOS,
Fig. 3. Dose-dependant activation of the ARE and MOS in hyperglycemia. A polyclonal HREC cell line transfected with ARE-GFP was incubated in
growth media with 5, 10, 30, and 55 mM glucose) for three days. After three days the cells were stained with Hoechst 33342 and CM-H2TMRos to label
nuclei and MOS positive cells, respectively. Cell counts (black bars) indicated hyperglycemic-toxicity, all cell counts are shown as a% of the negative
control (5 mM glucose). The percentage of apoptotic cells, as determined by nuclear morphology, is shown in the white bars. ARE-GFP activity is shown
as the percentage of cells with high levels of GFP ﬂuorescence (hatched bars). The percentage of MOS positive cells is shown with cross hatched bars.
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cose group were considered positive. The number of MOS
positive cells in the 30 mM glucose group was over 1.3-fold
more than the 10 mM group and the 55 mM group showed
the greatest fold increase of all of the groups at over 2-fold.
The vast majority of the GFP positive cells were also posi-
tive for MOS. This supports the hypothesis that MOS is
associated with ARE activation.Fig. 4. Relationship between MOS and ARE activity in vitro. HREC
were transiently transfected with ARE-GFP and incubated in 10, 30, and
55 mM glucose for 24 h. Flow cytometry was used to determine the fold
increase in the number of MOS, ARE/MOS, and ARE positive cells
compared to the 10 mM glucose group. The gray and black bars indicate
30 and 55 mM glucose levels, respectively.3.4. In vivo evaluation of nanoparticle-delivered ARE-GFP
Lewis rats were made diabetic with a single dose of Strep-
tozotocin. Diabetes was monitored by blood glucose levels.
Diabetic rats were maintained for one week prior to nano-
particle injection. The rats were maintained for three days
after sub-retinal injection with MNP-ARE-GFP. At 72 h
the rats were sacriﬁced and the eyecups ﬁxed overnight in
2% paraformaldehyde. The eyecups were washed and then
ﬂattened and photographed with confocal microscopy
(Fig. 5). The bleb site was immediately visible under trans-
mitted light. The bleb site of non-diabetic animals had very
few EGFP positive cells. This suggested that non-diabetic
retinas did not have highly activated ARE systems. Diabetic
animals had many more EGFP positive cells. These cells
appeared to be in a sheet and the morphology implied that
most of the EGFP positive cells were RPE.4. Discussion
Although oxidative stress is accepted as a major eﬀect of
hyperglycemia, oral and systemic antioxidants are ineﬀec-
tive in treating this. The reason may be that most destruc-
tive ROS are generated in mitochondria and traditional
antioxidants do not reach this site. Our data takes advan-
tage of the cells own antioxidant response to oxidative
stress, the ARE, to detect the presence of ROS in vivo.
It is well documented that pancreatic beta cells exposed
to hyperglycemia produce ROS and that this causes dys-
function of the beta cells in that glucose-induced insulin
secretion is suppressed (Sakai et al., 2003). Raza and
Fig. 5. ARE-tethered nanoparticle activity in normal and diabetic rats. Non-diabetic (top panels, non-diabetic) and diabetic (bottom panels, diabetic)
Lewis rats were injected, via sub-retinal route, with ARE-GFP-tethered nanoparticles. After three days the eyecups were photographed with confocal
microscopy. The ﬂattened z-stacks are shown in the left panels (2D) and 3D projections are shown in the right panels (3D).
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more severely eﬀected by mitochondrial ROS than liver
in STZ rats (Raza, Ahmed, & John, 2004). Kraus et al.
found that endogenous superoxide generated by hypergly-
cemia activates uncoupling protein 2 diverting energy away
from ATP synthesis and impairing glucose stimulated insu-
lin secretion (Krauss et al., 2003). Brownlee suggests that
the inhibition of mitochondrial superoxide overproduction
in b-cells exposed to hyperglycemia could prevent a posi-
tive feed-forward loop of glucotoxicity that drives impaired
glucose tolerance toward type 2 diabetes (Brownlee, 2003).
Oxidative stress has been implicated in a great variety of
disease states, including diabetes (Brownlee, 2003; Giardi-
no, Edelstein, & Brownlee, 1996; Wiernsperger, 2003).
The cell protects itself from oxidative insult through a vari-
ety of signaling pathways that converge onto the multitude
of promoter sequences found in the genomic DNA. From
bacteria to human beings, oxidative stress can be sensed
and responded to by a series of proteins including powerful
antioxidants and support enzymes. Oxidative stress is an
induced state whose levels are communicated through sig-
naling pathways, resulting the induction of antioxidantgenes as a protective measure in cells (Cory & Szentivanyi,
1987; Prochaska, De Long, & Talalay, 1985; Prochaska &
Talalay, 1988). These responses are coordinated through a
complex signaling network involving the antioxidant
response element (Friling, Bergelson, & Daniel, 1992;
Wasserman & Fahl, 1997). Recent work in the area of oxi-
dative stress has yielded anti-oxidant response element
based sensors that are capable of initiating reporter gene
expression in response to the presence of oxidative stress
inducing chemicals (Zhu, Chapman, Oberley, Wasserman,
& Fahl, 2001; Zhu & Fahl, 2000, 2001).
The ARE is composed of a cis-acting enhancer region
known as the ARE that is directly controlled by several
factors that include the transcription factor Nrf2, a repres-
sor Keap1, and small Maf proteins (Fig. 1). This system is
endogenously activated through the actions of oxidative
stress on the Keap1 protein (Dinkova-Kostova et al.,
2002). This protein normally represses the Nrf2 activator
by localizing Nrf2 in the cytoplasm. The activated ARE
enhances the expression of any gene downstream of its
sequence. Although the ARE can induce a variety of anti-
oxidant and supporting genes, the literature has repeatedly
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none oxidoreductases (Day, Suzuki, & Fanburg, 2003; Jai-
swal, 2000).
The reactive oxygen species-induced biosensor is a pro-
moter based system that relies on cellular machinery for the
detection of reactive oxygen species. The cell detects reac-
tive oxygen species and activates transcription factors
which bind to speciﬁc promoter regions. Transcription
downstream of these response elements, in this case a ﬂuo-
rescent reporter gene, is then activated. This construct is
composed of a number of antioxidant response element
repeats followed by a minimal Thymidine Kinase pro-
moter, ahead of a reporter gene, enhanced green ﬂuores-
cent protein or EGFP. The sensitivity of the biosensor is
dramatically aﬀected by the number of ARE repeats,
(Zhu & Fahl, 2000; Zhu et al., 2001).
This study utilizes ﬂuorescent dye and the ARE to detect
the cellular response to hyperglycemia in vitro. These data
show that the cell is quickly aﬀected by the presence of
hyperglycemia. Fluorescent dye sensitive to oxidation
showed that one of the early events in hyperglycemia-
induced pathology appears to be MOS. This supports the
hypothesis that MOS is a key player in hyperglycemia-
induced pathology. In our previous work, we have demon-
strated the use of a biosensor-tethered nanoparticle to
detect the cellular response to ROS insult in vitro (Prow
et al., 2006). Fig. 5 illustrates the use of that same technol-
ogy in vivo. The ARE-tethered nanoparticle was capable of
detecting the cellular response to the diabetic condition in
the eye. These data show that the cells in the retina are
responding in a way that strongly suggests ROS and pro-
vide the potential to detect ARE activity in the diabetic
retina.
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